Please ensure Javascript is enabled for purposes of website accessibility

Why Editas Medicine Stock Is Getting Crushed Today

By Prosper Junior Bakiny - Updated Apr 16, 2021 at 1:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are running for the hills following this analyst take on the biotech's prospects.

What happened

Shares of gene-editing specialist Editas Medicine (EDIT 15.57%) are falling sharply on Friday and were down by 16.7% as of 2:02 p.m. EDT. The company did not report any news, but these losses are probably a result of bearish commentary from a Wall Street analyst.

So what

Goldman Sachs analyst Madhu Kumar initiated coverage of Editas Medicine with a sell rating Friday. The analyst also gave the stock a price target of $20. Editas Medicine's share price as of the closing of business day yesterday was $40.98. And even after today's sell-off, Editas Medicine stock is priced at $34.21 (as of this writing), which means there remains a sizable downside for the biotech if we go by Kumar's price target.

Downward-bound graph on a blackboard.

Image source: Getty Images.

One reason behind the analyst's bearish sentiment is Editas Medicine's EDIT-101, a potential treatment for a rare eye disease called Leber congenital amaurosis. Initial results do not indicate that EDIT-101 could meaningfully improve patients' vision, according to Kumar. Overall, the analyst thinks the biotech's risk-reward profile is not attractive. 

Now what 

Should investors avoid Editas Medicine following this vote of no-confidence from Kumar? There is no question that the healthcare company has a long, arduous, and volatile road ahead. After all, it will be years before Editas Medicine can even hope to launch a product on the market, and a lot can happen in the meantime.

On the flip side, the company could go on to develop treatments for rare and otherwise difficult to treat illnesses thanks to its gene-editing technology. The success of its programs could translate into market-beating returns in the long run. In other words, Editas Medicine is a high-risk, high-reward play, but that's nothing new. In my view, investors with above-average risk tolerance -- and who are willing to be patient -- should still consider purchasing shares of this biotech stock.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Editas Medicine, Inc. Stock Quote
Editas Medicine, Inc.
$14.55 (15.57%) $1.96
The Goldman Sachs Group, Inc. Stock Quote
The Goldman Sachs Group, Inc.
$297.20 (-0.68%) $-2.03

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.